Compare CARS & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARS | IMMX |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 638.4M | 716.2M |
| IPO Year | 2017 | 2021 |
| Metric | CARS | IMMX |
|---|---|---|
| Price | $12.98 | $8.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $16.00 | ★ $19.20 |
| AVG Volume (30 Days) | 610.0K | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $723,239,000.00 | N/A |
| Revenue This Year | $3.03 | N/A |
| Revenue Next Year | $2.57 | N/A |
| P/E Ratio | $157.94 | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $7.40 | $1.94 |
| 52 Week High | $13.97 | $12.14 |
| Indicator | CARS | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 70.58 | 38.08 |
| Support Level | $10.61 | $7.99 |
| Resistance Level | $13.69 | $10.40 |
| Average True Range (ATR) | 0.47 | 0.75 |
| MACD | 0.06 | -0.27 |
| Stochastic Oscillator | 88.63 | 5.10 |
Cars.com Inc is an audience-powered and data-driven technology platform that simplifies buying and selling cars. The flagship Cars.com marketplace connects consumers to dealerships across the U.S., powering the car-buying experience with artificial intelligence (AI) shopping tools, vehicle reviews and content. Its ecosystem of products enables dealers and OEMs to sell more cars by leveraging the marketplace, dealer websites, trade and appraisal tools and proprietary in-market media solutions. The platform provides shoppers with data, resources and digital tools to make informed buying decisions and connect with automotive retailers. The Company also provides dealerships and OEMs with solutions and data-driven intelligence to reach and influence its 26 million monthly shoppers.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.